Related Experiment Video
Updated: May 19, 2026
Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
PGK1 epigenetically silences STING via DNMT1 and its knockdown synergizes with STING agonists in pancreatic cancer
Wan-Mei Liu1,2, Jia-Hui Xu1,3, Chun-Yong Ding4,5
1Shanghai Frontiers Science Center of Drug Target Identification and Delivery, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China.
Abstract:
The highly immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC) severely limits the efficacy of current immunotherapies. Identifying key molecular drivers of this immunosuppressive niche is therefore essential for developing new treatment strategies. In this study, through comprehensive bioinformatic analysis of PDAC clinical datasets and systematic experimental validation, we demonstrate that PGK1 is upregulated in PDAC and is associated with poor immune infiltration. Genetic knockdown of PGK1 upregulated STING expression, promoted the recruitment of antitumor immune cells into the tumor microenvironment, and significantly enhanced the in vivo efficacy of STING agonist treatment. Mechanistically, PGK1 stabilizes DNMT1 by blocking its ubiquitination-mediated degradation, which in turn promotes methylation of the STING promoter and suppresses its transcription. Our findings reveal a non-metabolic role of PGK1 in promoting an immunosuppressive microenvironment and propose a promising combination strategy targeting the PGK1-STING axis for the treatment of PDAC.
Insights
Phosphoglycerate kinase 1 (PGK1) promotes pancreatic cancer immune evasion by suppressing STING. Inhibiting PGK1 enhances anti-tumor immunity and immunotherapy efficacy, offering a new treatment strategy for pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits a highly immunosuppressive tumor microenvironment, hindering immunotherapy effectiveness.
- Identifying molecular regulators of this immunosuppressive niche is crucial for developing novel therapeutic strategies against PDAC.
Purpose of the Study:
- To investigate the role of phosphoglycerate kinase 1 (PGK1) in regulating the PDAC tumor microenvironment and immune cell infiltration.
- To elucidate the molecular mechanisms by which PGK1 influences the STING pathway and anti-tumor immunity in PDAC.
- To evaluate the therapeutic potential of targeting the PGK1-STING axis in PDAC treatment.
Main Methods:
- Comprehensive bioinformatic analysis of PDAC clinical datasets.
- Systematic experimental validation, including genetic knockdown of PGK1.
- Assessment of immune cell infiltration, STING expression, and tumor growth in vivo.
Main Results:
- PGK1 is upregulated in PDAC and correlates with reduced immune cell infiltration.
- Genetic knockdown of PGK1 increases STING expression and promotes antitumor immune cell recruitment.
- PGK1 stabilizes DNMT1, leading to STING promoter methylation and suppressed transcription.
- Targeting the PGK1-STING axis enhances the efficacy of STING agonist immunotherapy in vivo.
Conclusions:
- PGK1 plays a critical non-metabolic role in establishing an immunosuppressive tumor microenvironment in PDAC.
- The PGK1-DNMT1-STING axis represents a novel mechanism driving immune evasion in PDAC.
- Combination therapy targeting the PGK1-STING axis holds promise for improving immunotherapy outcomes in PDAC patients.
Related Concept Videos
01:58Cell Specific Gene Expression
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:34Inhibition of Cdk Activity